Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.

Blood - 29 Nov 2012

Shi Aibin, Murai Marcelo J, He Shihan, Lund George, Hartley Thomas, Purohit Trupta, Reddy Gireesh, Chruszcz Maksymilian, Grembecka Jolanta, Cierpicki Tomasz

Abstract excerpt

Menin functions as a critical oncogenic cofactor of mixed lineage leukemia (MLL) fusion proteins in the development of acute leukemias, and inhibition of the menin interaction with MLL fusion proteins represents a very promising strategy to reverse their oncogenic activity. MLL interacts with menin in a bivalent mode involving 2 N-terminal fragments of MLL. In the present study, we reveal the first...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crystallography, X-Ray
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HEK293 Cells

Share to Histone-Lysine N-Methyltransferase

Share to Immunoblotting

Share to Immunoprecipitation

Share to Leukemia

Share to Myeloid-Lymphoid Leukemia Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 22936661
DOI: 10.1182/blood-2012-05-429274
PMCID: PMC3512226

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.PMID 22936661Read ↗

Menin-MLL protein-protein interaction inhibitors: a patent review (2014–2021)Semantic proximity Read ↗

Molecular Basis of the Mixed Lineage Leukemia-Menin InteractionSemantic proximity Read ↗

Menin-MLL protein-protein interaction inhibitors: a patent review (2021-present).Semantic proximity Read ↗

A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL InhibitionSemantic proximity Read ↗

Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.Semantic proximity Read ↗

Characterization of the Menin-MLL Interaction as Therapeutic Cancer TargetSemantic proximity Read ↗

Menin: from molecular insights to clinical impactSemantic proximity Read ↗

Therapeutic Targeting of the Menin–KMT2A InteractionSemantic proximity Read ↗

Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 MutationSemantic proximity Read ↗

The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis.Semantic proximity Read ↗

Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?Semantic proximity Read ↗

Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.